Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy

Acta Oncologica

Volumn 46, Issue 5, 2007, Pages 639-650

  Larsen, Annette ^a,b   Bjørge, Benedikte ^c   Klementsen, Beate ^c   Helgeland, Lars ^b   Wentzel Larsen, Tore ^b   Fagerhol, Magne K ^d   Hovdenak, Nils ^b   Dahl, Olav ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c INSTITUTE OF MARINE RESEARCH   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; CALPROTECTIN; FATTY ACID; HEMOGLOBIN; LACTOFERRIN; LEUKOTRIENE B4; PROTEIN S 100; PROTEIN S 100 A12; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; FECES ANALYSIS; GASTROINTESTINAL TRACT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MALE; PELVIS; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM BIOPSY; RECTUM MUCOSA; SYMPTOMATOLOGY; TIME;

AGED; BIOLOGICAL MARKERS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PELVIS; PROCTITIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RECTUM;

EID: 34250354298     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860601099241     Document Type: Article

References (37)

1. Li L, Steinauer KK, Dirks AJ, Husbeck B, Gibbs I, Knox SJ. Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells. Radiat Res 2003;160:617-21.
2. Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000;48:325-8.
3. Cohn SM, Schloemann S, Tessner T, Seibert K, Stenson WF. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest 1997;99:1367-79.
4. Keskek M, Gocmen E, Kilic M, Gencturk S, Can B, Cengiz M, et al. Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats. J Surg Res 2006; (in press).
5. Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids 2002;37:935-40.
6. Cole AT, Slater K, Sokal M, Hawkey CJ. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. Gut 1993;34:1210-4.
7. Lifshitz S, Savage JE, Taylor KA, Tewfik HH, Van Orden DE. Plasma prostaglandin levels in radiation-induced enteritis. Int J Radiat Oncol Biol Phys 1982;8:275-7.
8. Hauer-Jensen M, Wang J, Denham JW. Bowel injury: Current and evolving management strategies. Semin Radiat Oncol 2003;13:357-71.
9. McGough C, Baldwin C, Frost G, Andreyev HJ. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer 2004;90:2278-87.
10. Guren MG, Schneede J, Tveit KM, Ueland PM, Nexo E, Dueland S. Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2004;60:807-13.
11. Guren MG, Tobiassen LB, Trygg KU, Drevon CA, Dueland S. Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer. Eur J Clin Nutr 2006;60:113-9.
12. Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapyinduced side effects. Support Care Cancer 2001;9:187-98.
13. Hovdenak N, Karlsdottir A, Sorbye H, Dahl O. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncol 2003;42:741-8.
14. Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: A sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1111-7.
15. Lie O, Lambertsen G. Fatty acid composition of glycerophospholipids in seven tissues of cod (Gadus morhua), determined by combined high-performance liquid chromatography and gas chromatography. J Chromatogr 1991;565:119-29.
16. Torstensen BE, Lie O, Froyland L. Lipid metabolism and tissue composition in Atlantic salmon (Salmo salar L.)-effects of capelin oil, palm oil, and oleic acid-enriched sunflower oil as dietary lipid sources. Lipids 2000;35:653-64.
17. Espe M, Kiessling A, Lunestad B-T, Torrisen O, Rora A. Quality of cold smoked salmon collected in one French hypermarket during a period of 1 year. Food Science Technol 2004;37:627-38.
18. Hamre K, Næss T, Espe M, Holm J, Lie O. A formulated diet for Atlantic halibut larvae. Acriculture Nutrition 2001;7:123-32.
19. Ton H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjonsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
20. Kristinsson J, Roseth A, Fagerhol MK, Aadland E, Schjonsby H, Bormer OP, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316-21.
21. Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen EK, Fagerhol MK. Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin. Scand J Immunol 2006; (in press).
22. Karlsdottir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 2004;71:43-53.
23. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
24. Dahl O, Horn A, Mella O. Do acute side-effects during radiotherapy predict tumour response in rectal carcinoma? Acta Oncol 1994;33:409-13.
25. Jereczek-Fossa BA, Jassem J, Badzio A. Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer. Int J Radiat Oncol Biol Phys 2002;52:476-82.
26. O'Brien PC, Franklin CI, Poulsen MG, Joseph DJ, Spry NS, Denham JW. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: Longer term follow-up of a phase III trial-Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:442-9.
27. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3-11.
28. Wang CJ, Leung SW, Chen HC, Sun LM, Fang FM, Huang EY, et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: Evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys 1998;40:85-91.
29. Khan AM, Birk JW, Anderson JC, Georgsson M, Park TL, Smith CJ, et al. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. Am J Gastroenterol 2000;95:1961-6.
30. Denham JW, Hauer-Jensen M. The radiotherapeutic injurya complex 'wound'. Radiother Oncol 2002;63:129-45.
31. Prasad KN, Cole WC, Kumar B, Che PK. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev 2002;28:79-91.
32. Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci USA 2005;102:13254-9.
33. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988;39:435-7.
34. Cengiz M, Akbulut S, Atahan IL, Grigsby PW. Acute phase response during radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:1093-6.
35. Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: A pilot study of eight stool markers. Scand J Gastroenterol 2004;39:1113-8.
36. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14.
37. Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 2003;35:607-9.